Bavarian Nordic

Perfil de la empresa

Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an oral vaccine for immunization against typhoid fever. It is also developing MVA-BN WEV, that is in phase 2 trial for the treatment of encephalitis viruses. It operates in the United States, Denmark, Canada, France, Germany, Singapore, England, Finland, Switzerland, Japan, Austria, Italy, Spain, Taiwan, Saudi Arabia, Australia, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.

Descripción disponible en inglés.

Datos societarios

Sector

Salud

Industria

Biotechnology

País

Dinamarca

Sede

Philip Heymans Alle 3, 2900, Hellerup

Empleados

1.906

Cotización

BAVA · Nasdaq Copenhagen

Divisa

DKK

ISIN

DK0015998017

Sitio web

bavarian-nordic.com